These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 6407285)
41. Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus. Hamaue N; Minami M; Terado M; Hirafuji M; Endo T; Machida M; Hiroshige T; Ogata A; Tashiro K; Saito H; Parvez SH Neurotoxicology; 2004 Jan; 25(1-2):205-13. PubMed ID: 14697895 [TBL] [Abstract][Full Text] [Related]
42. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment]. Jost WH; Klasser M; Reichmann H Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504 [TBL] [Abstract][Full Text] [Related]
43. Parkinson's disease: new treatments. Stewart RM Compr Ther; 1981 Apr; 7(4):38-44. PubMed ID: 7237986 [TBL] [Abstract][Full Text] [Related]
44. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy. Fischer PA J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073 [TBL] [Abstract][Full Text] [Related]
45. [Neuroprotective and neurorestorative therapy in Parkinson's disease]. Jiménez-Jiménez FJ; Molina JA Rev Neurol; 1997 Aug; 25 Suppl 2():S185-93. PubMed ID: 9280687 [TBL] [Abstract][Full Text] [Related]
46. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor. Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358 [No Abstract] [Full Text] [Related]
47. [Considerations in the drug treatment of parkinsonism (author's transl)]. Hungerbühler JP; Regli F Schweiz Rundsch Med Prax; 1978 Nov; 67(45):1648-57. PubMed ID: 30976 [No Abstract] [Full Text] [Related]
48. [Recent progress of therapy in patients with Parkinson's disease]. Yanagisawa N Nihon Naika Gakkai Zasshi; 1993 Jul; 82(7):1109-14. PubMed ID: 8228492 [No Abstract] [Full Text] [Related]
49. New strategies in the treatment of early Parkinson's disease. Rinne UK Acta Neurol Scand Suppl; 1991; 136():95-8. PubMed ID: 1801545 [TBL] [Abstract][Full Text] [Related]
50. Experience with tranylcypromine in early Parkinson's disease. Fahn S; Chouinard S J Neural Transm Suppl; 1998; 52():49-61. PubMed ID: 9564607 [TBL] [Abstract][Full Text] [Related]
51. Monoamine oxidase inhibitors and their pharmacological significance. Sandler M Acta Neurol Scand Suppl; 1983; 95():37-41. PubMed ID: 6428147 [TBL] [Abstract][Full Text] [Related]
52. [A contribution to the biochemical treatment of the akinetic type of the Parkinson's syndrome]. Völler GW Med Welt; 1968 Feb; 5():338-41. PubMed ID: 5668416 [No Abstract] [Full Text] [Related]
53. [Dopamine agonist in the treatment of Parkinson's disease]. Kuran W Neurol Neurochir Pol; 1997; 31(3):545-54. PubMed ID: 9446045 [TBL] [Abstract][Full Text] [Related]